Mixed
Achieving a body weight loss of 5% or greater within 12 weeks of initiating SGLT2 inhibitor treatment significantly reduces the risk of new-onset atrial fibrillation in patients with type 2 diabetes.
If you are taking an SGLT2 inhibitor for Type 2 Diabetes, aim for a body weight loss of at least 5% within the first 3 months. This specific threshold is associated with a significantly lower risk of developing atrial fibrillation compared to those who do not lose weight. However, this weight loss benefit did not extend to reducing heart failure hospitalizations or other major cardiovascular events in this study.
Compared with those without BW loss after SGLT2i treatment, AF risk significantly decreased with a BW loss of ≥ 5.0% (adjusted hazard ratios [95% confidence intervals]: 0.39[0.22–0.68]).
Why this rating
Large real-world observational database (n=10,237) with multivariate adjustment, though not a randomized controlled trial.
Source
The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium–glucose cotransporter 2 inhibitor
Yi‐Hsin Chan et al. · Cardiovascular Diabetology · 2021
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →